MDL | MFCD00003420 |
---|---|
Molecular Weight | 78.00 |
Molecular Formula | AlH3O3 |
SMILES | O[Al](O)O |
Aluminum Hydroxide is an orally active main form of aluminum used as adjuvant. Aluminum hydroxide-based adjuvant researches include the repository effect, pro-phagocytic effect, and activation of the pro-inflammatory NLRP3 pathway. Aluminum Hydroxide also acts as adjuvant to compensate low inherent immunogenicity of subunit vaccines [1] [2] .
Aluminum Hydroxide (orally; 100 mg/kg/day for 7 days) increases lipid peroxidation and decreases the activity of SOD in the brain. Aluminum Hydroxide can dissolve in distilled water to be a homogeneous suspension [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00031109 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Not Applicable | |
NCT01837446 | Isfahan University of Medical Sciences |
Stomatitis
|
July 2011 | Phase 2|Phase 3 |
NCT00000809 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections|HIV Seronegativity
|
Phase 1 | |
NCT01376765 | National Institute of Allergy and Infectious Diseases (NIAID) |
SARS
|
Phase 1 | |
NCT04915768 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
May 3, 2021 | Phase 1 |
NCT03755427 | Shanghai Institute Of Biological Products |
H7N9 Influenza
|
November 2018 | Phase 2 |
NCT00854776 | Taipei Veterans General Hospital, Taiwan |
Peptic Ulcer|Ulcer Complications
|
January 2009 | Not Applicable |
NCT02298179 | GlaxoSmithKline |
Respiratory Syncytial Virus (RSV)
|
December 19, 2014 | Phase 1 |
NCT00001906 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Cutaneous Leishmaniasis
|
April 1999 | Phase 1 |
NCT03589768 | National Institute of Allergy and Infectious Diseases (NIAID) |
Clostridium Difficile Immunisation|Diphtheria|Diphtheria Immunisation|Pertussis|Tetanus|Tetanus Immunisation
|
January 24, 2019 | Phase 2 |
NCT00280033 | National Institute of Allergy and Infectious Diseases (NIAID) |
Influenza
|
February 2006 | Phase 1|Phase 2 |
NCT00974935 | National Institute of Allergy and Infectious Diseases (NIAID) |
Toxic Shock Syndrome Staphylococcal
|
February 2011 | Phase 1 |
NCT02116998 | Genocea Biosciences, Inc. |
Pneumococcal Infections|Pneumonia, Pneumococcal
|
September 2014 | Phase 2 |
NCT00263744 | MedImmune LLC|GlaxoSmithKline |
Healthy
|
November 1999 | Phase 1|Phase 2 |
NCT00000779 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
NCT05561673 | GlaxoSmithKline |
Hepatitis B
|
October 4, 2022 | Phase 1|Phase 2 |
NCT00001042 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
NCT00529399 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Center for Research Resources (NCRR)|American Diabetes Association|Juvenile Diabetes Research Foundation |
Type 1 Diabetes Mellitus
|
February 2009 | Phase 2 |
NCT00001052 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
NCT03382418 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
December 27, 2017 | Phase 1 |
NCT00296634 | National Institute of Allergy and Infectious Diseases (NIAID) |
Influenza
|
March 2006 | Phase 1|Phase 2 |
NCT00294099 | National Institute of Allergy and Infectious Diseases (NIAID) |
Influenza
|
March 2006 | Phase 1|Phase 2 |
NCT01280968 | Alexey Mukhin|Wake Forest University Health Sciences|Novartis Pharmaceuticals|Duke University |
Nicotine Dependence
|
December 2010 | Phase 2 |
NCT00002402 | VaxGen|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 1 | |
NCT00000868 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections|HIV Seronegativity
|
Phase 1 | |
NCT02067676 | U.S. Army Medical Research and Development Command|Walter Reed Army Institute of Research (WRAIR) |
Campylobacter Infection
|
April 21, 2014 | Phase 1 |
NCT00001053 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
NCT03369808 | Shanghai Institute Of Biological Products|Henan Center for Disease Control and Prevention |
H7N9 Influenza
|
December 29, 2017 | Phase 1|Phase 2 |
NCT00018135 | National Center for Research Resources (NCRR) |
Renal Failure
|
Not Applicable | |
NCT03049488 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Respiratory Syncytial Virus
|
February 22, 2017 | Phase 1 |
NCT00533741 | National Institute of Allergy and Infectious Diseases (NIAID) |
Coronavirus (SARS-CoV)
|
Phase 1 | |
NCT05131295 | El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez |
Subarachnoid Hemorrhage|Brain Ischemia|Subarachnoid Hemorrhage, Aneurysmal|Aneurysmal Subarachnoid Hemorrhage|Delayed Cerebral Ischemia|Vasospasm, Cerebral
|
September 5, 2007 | Phase 3 |
NCT00001044 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
NCT00382980 | National Institute of Allergy and Infectious Diseases (NIAID) |
Influenza
|
October 2006 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : < 1 mg/mL (ultrasonic) (insoluble or slightly soluble)
Add each solvent one by one: 0.5% CMC-Na /saline water
Solubility: 10 mg/mL (128.21 mM); Suspended solution; Need ultrasonic